Should IVIG dosing in patients with autoimmune disease (i.e., dermatomyositis) who become pregnant continue to be based on actual weight at the time of each infusion, or should it be limited to pre-pregnancy weight?

This is a very interesting and incredibly pragmatic question, but not one with an easy answer.

By way of background:

The treatment of pregnant DM patients is understandably complicated by the need to balance adequately treating disease activity against the maternal/fetal toxicity of medications. In ad...

I very much agree with what is written by Dr. @Dr. First Last. I often use IVIG in pregnancy for myositis patients as well as those with autoimmune cytopenias. I stay with prepregnancy dosing. However, if active disease, I would certainly change. The AAP has a nice review from 2021 on the safety of ...